L- alpha-glycerylphosphorylcholine

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of L-alpha-glycerylphosphorylcholine
General
Surname L- alpha-glycerylphosphorylcholine
other names
  • alpha-GPC
  • Choline foscerate
  • ( 2R ) -2,3-dihydroxypropyl-2- (trimethylammonio) ethyl phosphate
  • sn-glycero-3-phosphocholine
  • Delecit
Molecular formula C 8 H 20 NO 6 P
Brief description

Crystalline solid

External identifiers / databases
CAS number 28319-77-9
EC number 248-962-2
ECHA InfoCard 100,044,496
PubChem 657272
DrugBank DB04660
Wikidata Q28529699
Drug information
ATC code

N07 AX02

Mechanism of action

Hormone precursor

properties
Molar mass 257.22 g · mol -1
Physical state

firmly

Melting point

152 ° C

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling
no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

L- alpha-glycerylphosphorylcholine (α-GPC, cholinalfoscerate) is a metabolite of the phospholipid phosphatidylcholine . It occurs naturally in the brain and kidneys . It is a parasympathomimetic predecessor of the neurotransmitter acetylcholine . Alpha-GPC canpenetratethe blood-brain barrier and is therefore a source for the rapid supply of choline in the brain, where it is used for the synthesis of acetylcholine. In kidneys, α-GPC serves as an osmolyte for osmoregulation . In the USA, α-GPC isclassifiedas Generally Recognized As Safe by the FDA .

A use of α-GPC for the treatment of Alzheimer's disease and dementia is being investigated.

literature

  • SK Tayebati, F. Amenta: Choline-containing phospholipids: relevance to brain functional pathways . In: Clinical Chemistry and Laboratory Medicine . tape 51 , no. 3 , 2013, p. 513-521 , doi : 10.1515 / cclm-2012-0559 , PMID 23314552 .

Individual evidence

  1. a b Patent WO9315088 : Crystallization process for preparing glycerophosphocholine. Filed December 31, 1992 , published August 5, 1993 Inventors: Christopher T. Evans, Raymond Mccague, Nicholas D. Tyrrell.
  2. This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  3. M. de Jesus Moreno Moreno: Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial . In: Clinical Therapeutics . tape 25 , no. 1 , 2003, p. 178-193 , doi : 10.1016 / S0149-2918 (03) 90023-3 , PMID 12637119 .
  4. L. Parnetti et al. : Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? In: Journal of the Neurological Sciences . tape 257 , no. 1–2 , 2007, pp. 264-269 , doi : 10.1016 / j.jns.2007.01.043 , PMID 17331541 .
  5. M. Gallazzini, MB Castle: What's new about osmotic regulation of glycerophosphocholine . In: Physiology (Bethesda) . tape 24 , no. 4 , 2009, p. 245–249 , doi : 10.1152 / physiol.00009.2009 , PMID 19675355 , PMC 2943332 (free full text).
  6. GRAS Notices 419: L-alpha-glycerylphosphorylcholine. FDA.gov, PDF .
  7. ^ E. Traini, V. Bramanti, F. Amenta: Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent . In: Current Alzheimer Research . tape 10 , no. 10 , 2013, p. 1070-1079 , PMID 24156263 .
  8. PL Scapicchio: Revisiting choline alphoscerate profile: a new, perspective, role in dementia? In: The International Journal of Neuroscience . tape 123 , no. 7 , 2013, p. 444-449 , doi : 10.3109 / 00207454.2013.765870 , PMID 23387341 .